New England Journal of Medicine

Targeted Immunomodulation Transforms Dermatomyositis Management: Phase 3 Brepocitinib Trial Demonstrates Significant Clinical Benefits

Post author:Bree Clare
Post published:April 16, 2026
Post category:Dermatomyositis

Researchers have demonstrated substantial therapeutic benefits for brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, in adults with dermatomyositis, according to findings from a Phase 3 clinical trial published…

FDA Fast-Tracks Vera Therapeutics’ Atacicept as Potential Gamechanger for IgA Nephropathy Treatment

Post author:Bree Clare
Post published:January 30, 2026
Post category:IgA Nephropathy (IgAN)

Vera Therapeutics announced a major milestone in drug development on January 7, 2026, when the U.S. Food and Drug Administration granted Priority Review to the Biologics License Application (BLA) for…

source: pixabay.com

Patients with Severe AKI Don’t Benefit from Accelerated Therapy

Post author:Jessica Lynn
Post published:July 28, 2020
Post category:Chronic Kidney Disease Proteinuria

There's no misunderstanding this fact: renal-replacement therapy is effective for patients with severe acute kidney injuries (AKI). However, states Kenny Walter in MD Magazine, the efficacy of this treatment can depend…

Targeted Immunomodulation Transforms Dermatomyositis Management: Phase 3 Brepocitinib Trial Demonstrates Significant Clinical Benefits

FDA Fast-Tracks Vera Therapeutics’ Atacicept as Potential Gamechanger for IgA Nephropathy Treatment

Patients with Severe AKI Don’t Benefit from Accelerated Therapy

Let’s Work Together!

Keep Up to Date

Learn More